



Cite this: *RSC Adv.*, 2017, 7, 31133

# A multifunctional nanoplatform based on mesoporous silica nanoparticles for imaging-guided chemo/photodynamic synergetic therapy†

Yadan Liu,<sup>ab</sup> Xiaolin Liu,<sup>a</sup> Yue Xiao,<sup>ab</sup> Fangman Chen<sup>ab</sup> and Fangnan Xiao<sup>ab\*</sup>

Multifunctional nanoplatforms based on mesoporous silica nanoparticles (MSNs) have recently shown great promise in drug delivery and therapy. Herein, a multifunctional nanoplatform based on MSNs is fabricated by a modified micro-emulsion method for drug delivery and imaging-guided chemo/photodynamic synergistic therapy. Carbon dots (C-dots) and a photosensitizer, rose bengal (RB), are embedded in the core/shell structured MSNs to form MSN@C-dots/RB nanoparticles, in which C-dots can serve as a fluorescence probe to achieve cell fluorescence imaging and RB can generate singlet oxygen to perform photodynamic therapy. MSN@C-dots/RB nanoparticles can efficiently prevent the self-aggregation-induced quenching of photosensitizer molecules, which facilitates a large production of cytotoxic singlet oxygen and thus an enhanced PDT efficacy. Furthermore, a remarkable chemo/photodynamic synergistic anti-tumor effect was achieved with MSN@C-dots/RB nanoparticles loaded with doxorubicin (DOX) under green light irradiation. In addition, a significant bacterial inhibitory effect has been achieved by the antimicrobial assay *via* loading ampicillin in the MSNs@C-dots/RB nanoparticles, thereby demonstrating the versatility of this multifunctional nanoplatform. The results revealed that this MSN-based chemo/photodynamic synergistic nanoplatform has great promise in imaging assisted cancer therapy and bacteria inhibition.

Received 23rd April 2017  
 Accepted 11th June 2017

DOI: 10.1039/c7ra04549b

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## Introduction

With the development of biomedicine, the establishment and application of multifunctional therapy nanoplatforms has become a new trend for cancer therapy.<sup>1,2</sup> Nanoplatforms integrated with diagnostic and therapeutic functions (*e.g.*, multi-modal imaging, targeted delivery, synergistic therapy) have been widely researched.<sup>3,4</sup> For example, Liu *et al.* synthesized a multifunctional polymeric nano-micelle system, containing the photosensitizer chlorin e6 (Ce6), Gd<sup>3+</sup> and the near-infrared (NIR) dye, IR825. The use of these micelles as a contrast agent achieved triple modal imaging of tumors *in vivo*. The combination of photothermal and photodynamic therapies has remarkably brought about both *in vitro* and *in vivo* synergistic anti-tumor effects.<sup>5</sup> In recent years, various materials, such as metals, silica, graphene, polymers, metal organic frameworks (MOF) and clay, have been used for constructing multifunctional drug systems.<sup>6–13</sup> Among the current nanoplatforms, the

mesoporous silica nanoparticles (MSNs) have been developed as a promising candidate for multifunctional cancer therapy owing to their high surface area, large pore volume with tunable pore sizes, facile surface modification, high light transparency and good biocompatibility.<sup>7,14–17</sup> For example, MSN@Fe<sub>3</sub>O<sub>4</sub>-FITC nanoparticles have been developed for MR and luminescence imaging of NIH 3T3 fibroblast cells.<sup>18</sup> PEG-silica nanoplatforms have been designed as nanocarriers of doxorubicin (DOX) for cancer therapy and show significantly increased liver tumor inhibition rate and decreased toxicity.<sup>19</sup> Folate-MSNs exhibit escaping endosomal entrapment and enhance the HeLa cellular uptake of these materials.<sup>20</sup>

Rose bengal (RB) is a well-known green light-activated photosensitizer that shows absorption bands in the visible range (480–550 nm) and high singlet oxygen quantum yield ( $\Phi(^1O_2) = 0.75$ ).<sup>21–23</sup> RB-MSN nanoplatforms have been reported for photodynamic therapy.<sup>24–26</sup> For example, RB can be covalently bound to MSN by thiolene click chemistry method and showed highly effective antibacterial activity.<sup>23</sup> RB-modified MSN displayed high photostability and efficiency in the photoproduction of singlet oxygen.<sup>21,22</sup> PEG-modified RB-loaded MSN exhibits about 10 times apoptosis efficiency than that of free RB.<sup>26</sup> Although great progress has been achieved in the development of MSN-based nanoplatforms, several challenges still exist in multifunctional MSNs as drug systems for clinic application. First, the complexity of components in a single

<sup>a</sup>State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian 350002, China. E-mail: [fnxiao@fjirsm.ac.cn](mailto:fnxiao@fjirsm.ac.cn)

<sup>b</sup>College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7ra04549b



nanoparticle will bring a mutual interference between dyes and/or nanoparticles, which reduces diagnostic and therapeutic efficacy. Therefore, many studies are undergoing to design various structures such as hollow, core/shell to control these side-effects.<sup>14,17,19</sup> Second, the incorporation of multiple types of drugs into one nanoparticle makes it difficult to obtain high encapsulation efficiency for each drug. It could also influence the drug release kinetic and release mode. Hence, various methods have been developed including the doping of silica with drugs during preparation and co-condensation of silica source (e.g., organosilane).<sup>27–29</sup> For example, the photosensitizer porphyrin derivatives can be covalently encapsulated inside MSN for photodynamic therapy.<sup>30</sup> The porphyrin–MSN can also load DOX in the pore of MSN for chemo/photodynamic therapy.<sup>31</sup> Third, many methods involving multiple steps are costly.<sup>7,19,20,32</sup> Therefore, MSN-based nanoplatfoms are still in the early stage for applications.

As the emerging fluorescence nanomaterial, carbon dot (C-dot) has unique properties, such as the tunable fluorescence emission, chemical inertness and excellent biocompatibility.<sup>33–38</sup> They are becoming widely used to facilitate the construction of multifunctional medical nanomaterials.<sup>34,39–41</sup> However, due to their aggregation-induced luminescence quenching property, the photoluminescence effect of C-dots was seriously destroyed at the high concentrations of the C-dots, leading to serious hindrance of their application in bio-imaging.<sup>42</sup> Hence, many materials have been used for dispersion and encapsulation of C-dots to avoid the undesirable effects.<sup>43–47</sup> For example, the fluorescent of carbon dot–MSNs can be enhanced by Ag based on the metal-enhanced fluorescence effect.<sup>48</sup> In addition, highly luminescent organosilane-functionalized C-dots were synthesized,<sup>46</sup> which were demonstrated to be used for Cu<sup>2+</sup> detection.<sup>49</sup> Because the stability and biocompatibility were greatly improved by silica-coating.<sup>44,45,50–52</sup> C-dots@MSN nanoparticles have been developed for molecular delivery, where C-dots on the surface of MSNs were used as cell imaging agent, and the large pore volume of MSNs can load the chemotherapeutic drugs for cancer therapy.<sup>53</sup>

In this study, a multifunctional nanoplatfom based on MSNs carrying C-dots and a photosensitiser rose bengal (RB) was designed for drug delivery, synergistic chemo/photodynamic cancer therapy and inhibition of bacteria. This nanoplatfom consisted of two mesoporous layers with C-dots and RB embedded in different layers, respectively. C-dots were used for cell fluorescence imaging. RB was introduced to achieve the effective photodynamic therapy and fluorescence imaging. The MSNs embedding C-dots systems maintained the excellent fluorescence properties of C-dots, and benefited further application of bioimaging and therapy. Meanwhile, the epitaxial growth characteristic of the mesoporous silica shell on MSNs avoided the mutual interference between C-dots and RB to realize photodynamic therapy (PDT). Furthermore, DOX loaded in the pore of MSNs for chemotherapy. The results exhibited significantly increasing cancer therapy in human lung cancer cell line NCI-H1299 (H1299) due to the synergistic chemo/photodynamic effect. And this MSN@C-dots/RB multi-function nanoplatfom also showed good bacteria (*E. coli*)

inhibition and thereby could achieve more effective therapeutic effects in cancer therapy, since frequently the bacterial infection accompanying cancer progression can injure the immune system and deteriorate cancers.<sup>54</sup> Compared to other nanoplatfoms, our design had the advantages to avoid the mutual interference between C-dots and RB, and guarantee an economic strategy for synergistic effects on cancer therapy and bacteria inhibition.

## Experimental

### Chemicals and materials

Sodium hydroxide (NaOH), citric acid, urea, rose bengal (RB), tetraethylorthosilicate (TEOS), cetyltrimethylammonium chloride (CTAC), 1,3-diphenylisobenzofuran (DPBF), triethanolamine (TEA), dimethylformamide (DMF), and ethanol were purchased from Sinopharm Chemical Reagent Co., China. Hoechst 33342 and 1-octadecene were purchased from Sigma-Aldrich (China). All the chemical reagents were of analytical grade and used as received without further purification.

### Synthesis of carbon dots

The C-dots were prepared by previous methods.<sup>35</sup> In detail, citric acid (1 g), urea (2 g) and DMF (10 mL) were added into a 20 mL Teflon stainless steel autoclave and reacted at 160 °C for 6 h. The obtained solution was mixed with NaOH (20 mL, 50 mg mL<sup>-1</sup>), and centrifuged at 16 000 rpm min<sup>-1</sup> for 10 min. The precipitate was redispersed in water, centrifuged. The freeze-dried product C-dots were got.

### Preparation of carbon dots embedded mesoporous silica nanoparticles (MSN@C-dots)

MSN@C-dots nanoparticles were achieved by a modified micro-emulsion method. C-dots were doped in the process of MSN@C-dots nanoparticles preparation. The MSNs were prepared *via* an oil–water biphasic stratification approach by using cationic surfactant CTAC as a template, TEOS as a silica source, TEA as a catalyst and organic solvent 1-octadecene or cyclohexane as an emulsion agent.<sup>32</sup> A typical synthesis of the carbon dots doped mesoporous silica nanospheres (MSN@C-dots) was performed as following. Firstly, CTAC solution (12 mL, 25 wt%), carbon dots solution (2.5 mL, 1 mg mL<sup>-1</sup>) and TEA (0.09 g) were sequentially added to water (18 mL) and stirred mildly at 60 °C for 1 h in a 50 mL round bottom flask, then TEOS solution in 1-octadecene (10 mL, 20 v/v%) was slowly added to the water–CTAC–TEA solution and kept at 60 °C in an oil bath under a gentle magnetic stirring. Then the reaction was kept at a constant temperature with continuous stirring for 12 h to obtain the products. After that, the upper phase, 1-octadecene solution was completely removed and the products were collected by centrifugation and washed with ethanol for 4 times to remove the residual reactants. Then, the collected products were extracted with ammonium nitrate (NH<sub>4</sub>NO<sub>3</sub>) ethanol solution (50 mL, 0.6 wt%) at 60 °C for 12 h to remove the template, and centrifuged at 16 000 rpm min<sup>-1</sup> for 10 min. The precipitate was collected, dissolved in ethanol and centrifuged



twice, and then freeze-dried to get the brown products of MSN@C-dots nanoparticles.

### Preparation of MSN@C-dots/RB nanoparticles

The synthesis of the MSN@C-dots/RB was following with the preparation of MSN@C-dots. At first, CTAC solution (12 mL, 25 wt%), carbon dots solution (2.5 mL, 1 mg mL<sup>-1</sup>) and TEA (0.09 g) were sequentially added to water (18 mL) and stirred mildly at 60 °C for 1 h in a 50 mL round bottom flask, then TEOS solution in 1-octadecene (10 mL, 20 v/v%) was slowly added to the water-CTAC-TEA solution and kept at 60 °C in an oil bath under a gentle magnetic stirring. Then the reaction was kept at a constant temperature with continuous stirring for 12 h to obtain the products. Then, the upper phase, 1-octadecene solution was completely removed and the products were collected by centrifugation and washed for several times with ethanol to remove the residual reactants. Then, the collected products, rose bengal solution (1 mL, 2 mM mL<sup>-1</sup>), CTAC solution (12 mL, 25 wt%) and TEA (0.09 g) were added to water (18 mL) and stirred gently at 60 °C for 1 h in a 50 mL round bottom flask. Then TEOS solution in cyclohexane (10 mL, 20 v/v%) was slowly added and kept at 60 °C for another 12 h for the growth of the RB embedded MSNs shell. The products were collected by centrifugation and washed for several times with ethanol to the residual reactants. Then, the collected products were extracted with a 0.6 wt% ammonium nitrate (NH<sub>4</sub>NO<sub>3</sub>) ethanol solution at 60 °C for 24 h to remove the template and centrifuged at 16 000 rpm min<sup>-1</sup> for 10 min. The precipitate was collected, dissolved in ethanol and centrifuged twice, and then freeze-dried to get the pink products of MSN@C-dots/RB nanoparticles.

### Measurement of the loading capacity of photosensitizer in MSN@C-dots/RB nanoparticles

The content of RB doped in MSN@C-dots/RB nanoparticles was determined by measuring the characteristic emission peak of RB at 540 nm for the solution of MSN@C-dots/RB nanoparticles (100 µg mL<sup>-1</sup>). The weight amount of RB embedded in MSN@C-dots/RB nanoparticles could be calculated based on the standard curve derived from the emission spectra of the different concentrations of pure RB solution. The loading capacity of RB was calculated as follows: loading capacity (%) = (weight amount of RB in MSN@C-dots/RB nanoparticles)/(weight amount of MSN@C-dots/RB nanoparticles) × 100%.

### Measurement of the release of photosensitizers from MSN@C-dots/RB nanoparticles

Firstly, MSN@C-dots/RB nanoparticles (4.0 mg) were soaked in PBS buffer (1 mL) with different pH (pH = 5.0, 6.0, 6.5, and 7.0) under continuous stirring at 37 °C in darkness. After soaking for 72 h, the solution of MSN@C-dots/RB nanoparticles was centrifuged at 16 000 rpm for 5 min. The corresponding supernatant was then assessed to determine whether the photosensitizers were released into solution by measuring their emission spectra.

### Singlet oxygen detection

A chemical probe 1,3-diphenylisobenzofuran (DPBF) was used to confirm the <sup>1</sup>O<sub>2</sub> generation by detecting its absorption intensity at 415 nm *via* UV-Vis spectroscopy. In a typical experiment, DPBF in ethanol (10 µL, 5 mM) was added to ethanol/H<sub>2</sub>O solution (50 v/v%) containing MSN@C-dots/RB nanoparticles (3 mL, 0.1 mg mL<sup>-1</sup>). The solution was kept in the dark and irradiated with a 540 nm lamp (300 mW cm<sup>-2</sup>) for 10 min, and the absorption intensity of DPBF at 415 nm was recorded every 1 min. In the control experiments, DPBF absorption was recorded in MSN@C-dots nanoparticles counterparts or in the absence of 540 nm irradiation under otherwise identical conditions.

### DOX loading and releasing

MSN@C-dots/RB nanoparticles (12 mg) was mixed with PBS (10 mL, pH 7.4) containing 5 mg of DOX. After stirring for 12 h in the dark, the DOX loaded MSN@C-dots/RB nanoparticles were collected by centrifugation. The samples were washed with PBS for several times. The content of DOX was determined by detecting the absorption spectra of supernatant and original DOX solution at 482 nm. The DOX loading capacity and loading efficiency were calculated as follows: DOX loading capacity (wt%) = (original DOX – DOX in supernatant)/(MSN@C-dots/RB nanoparticles) × 100% and DOX loading efficiency (wt%) = (original DOX – DOX in supernatant)/(original DOX) × 100%. The DOX releasing experiments were carried out in PBS buffer at different pH (pH 5.0, 6.0, and 7.0). MSN@C-dots/RB/DOX nanoparticles (2.0 mg) were dispersed in PBS buffer (2 mL) and then incubated at 37 °C with gentle shaking in darkness. 100 µL of supernatant was taken out after centrifugation at specified time points to detect the absorption spectra at 482 nm. The equal volume of fresh PBS buffer with different pH was added to keep the total volume constant.

### Cell culture and confocal laser scanning microscopy imaging

Human lung cancer cells (H1299) and human embryo lung fibroblasts cells (HELFL) cell lines were purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences, and were routinely maintained in RPMI-1640, supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS), penicillin (100 U mL<sup>-1</sup>), and streptomycin (100 mg mL<sup>-1</sup>) at 37 °C under humidified air containing 5% CO<sub>2</sub>. H1299 cells were seeded into culture plates and allowed to adhere for 24 h. After washing with PBS, the cells were incubated in culture medium containing MSN@C-dots/RB nanoparticles at 37 °C for 2 h under 5% CO<sub>2</sub> and then washed with PBS sufficiently to remove excess nanoparticles. The cells were subsequently incubated with Hoechst 33342 at RT for 10 min and washed with PBS. The cell imaging was performed with a laser scanning confocal fluorescence microscope (Leica SP5). The luminescence signals were detected in the green channel (565–590 nm), red channel (590–680 nm) and blue channel (450–490 nm), respectively.





## Cell viability assay

H1299 cells at a density of  $5 \times 10^4$  cells per milliliter were placed in 96-well plates with a volume of 200  $\mu\text{L}$  per well and incubated overnight at 37 °C under 5%  $\text{CO}_2$ . The culture medium was carefully removed and the cells were incubated with different concentrations of MSN@C-dots/RB nanoparticles or MSN@C-dots/RB/DOX nanoparticles (0, 10, 30, 50, 80 and 100  $\mu\text{g mL}^{-1}$ ) diluted with fresh culture medium for 4 h. The cells were incubated with fresh culture medium as the control. The cells were then washed twice with sterile PBS before fresh culture medium was added. For PDT experiment, the cells were exposed to 540 nm irradiation with a power density of 300  $\text{mW cm}^{-2}$  for 5 min. Then the cells were cultured in 5%  $\text{CO}_2$  at 37 °C for additional 24 h. MTT was subsequently added to the cells followed by incubation at 37 °C under 5%  $\text{CO}_2$  for 4 h, and then the culture medium was carefully discarded and replaced with DMSO. The  $\text{OD}_{490}$  value of each well was measured on a multimodal microplate reader (Synergy 4, BioTek). The following formula was applied to calculate the percent inhibition rate of cell growth: cell viability (%) = (mean of absorbance value of treatment group/mean of absorbance value of control)  $\times$  100%. Four replicates were run per nanoparticles dose in each cell lines. The same protocol was utilized to determine the cytotoxicity of MSN@C-dots/RB nanoparticles to HELF cells, except that the HELF cells were incubated with nanoparticles for 24 h without PDT treatment.

## Antimicrobial activity measurement of the MSN@C-dots/RB nanoparticles

For ampicillin storage, the as-obtained MSN@C-dots/RB nanoparticles (20 mg) was mixed with 500  $\mu\text{L}$  of ampicillin aqueous solution (100  $\text{mg mL}^{-1}$ ) under a magnetic stirring at 37 °C for 12 h in dark. The excess amount of ampicillin was removed by centrifugation and washing with deionized water for several times. The content of ampicillin was determined by detecting the UV absorption spectra of supernatant and original ampicillin solution at 263 nm. The Amp loading capacity and loading efficiency were calculated as follows: Amp loading capacity (wt%) = (original Amp – Amp in supernatant)/(MSN@C-dots/RB nanoparticles)  $\times$  100% and Amp loading efficiency (wt%) = (original Amp – Amp in supernatant)/(original Amp)  $\times$  100%. *Escherichia coli* (*E. coli*, a kind of Gram-negative bacteria) was used as model in our experiment. The *E. coli* was grown in LB medium on a shaking incubator (170 rpm) at 37 °C overnight for bacterial growth into exponential phase. Bacterial suspensions diluted to  $1 \times 10^4$  times was treated with different concentrations of MSN@C-dots/RB or MSN@C-dots/RB/Amp with three parallel samples for each group and exposed to 540 nm irradiation with a power density of 300  $\text{mW cm}^{-2}$  for 10 min. Then *E. coli* was grown in LB medium on a shaking incubator (230 rpm) at 37 °C for 20 h. 100  $\mu\text{L}$  liquids was taken out from the flask at predetermined time points and the values of the optical density (OD) at 600 nm were record. For agar plate experiments, the bacterial suspensions was diluted  $10^4$  times and incubated with 100  $\mu\text{g mL}^{-1}$  of MSN@C-dots/RB or MSN@C-dots/RB–Amp on a shaking incubator (230 rpm) at 37 °C for 1 h. Then *E. coli* was

exposed to 540 nm irradiation with a power density of 300  $\text{mW cm}^{-2}$  for 10 min. 100  $\mu\text{L}$  of the bacterial suspensions was spread onto the agar plates and the agar plates were then inverted and incubated at 37 °C for 12 h. Photographs of *E. coli* colonies grown on the agar plates were obtained.

## Structural and optical characterization

Transmission electron microscopy (TEM) measurements were performed on a Tecnai F20 TEM equipped with the energy-dispersive X-ray spectrum. The hydrodynamic diameter distribution of MSN@C-dots nanoparticles and MSN@C-dots/RB nanoparticles were determined by means of dynamic light scattering (DLS) measurement (Nano ZS ZEN3600, Malvern).  $\text{N}_2$  sorption/desorption measurements were performed on a Micromeritics ASAP2020M instrument at 77 K. UV-Vis absorption spectra were measured with a Perkin-Elmer Lambda 950 UV/Vis/NIR spectrometer. Emission spectra were recorded on an Edinburgh Instrument FLS920 spectrofluorometer equipped with both continuous (450 W) xenon and pulsed flash lamps. Thermogravimetric analyses (TGA) was determined by STA449C (NETZSCH). MTT assay was measured on a multimodal microplate reader (Synergy 4, BioTek). The cell imaging was performed with a Leica SP5 laser scanning confocal fluorescence microscope.

## Results and discussion

### Characterization of the MSN@C-dots/RB nanoparticles

The MSN@C-dots/RB nanoparticles were prepared for cell imaging, drug release, and photodynamic therapy, as shown in the schematic illustration (Fig. 1). As shown in Fig. 1, C-dots, MSN@C-dots, MSN@C-dots/RB and the drug loading MSN@C-dots/RB nanoparticles were prepared sequentially. C-dots were prepared using solvent-thermal method,<sup>35</sup> and the average particle size was proved to be  $3.9 \pm 0.8$  nm (Fig. 2a and d). With C-dots embedded in the mesoporous silica (MS) matrix, MSN@C-dots nanoparticles had stable structure and uniform spherical morphology with a diameter of about  $79.1 \pm 2.7$  nm (Fig. 2b and e), and the worm-like mesoporous channels extending to the surface of the nanoparticles can be clearly observed in the nanoparticles. The energy-dispersive X-ray spectroscopy (EDX) of the MSN@C-dots nanoparticles showed




Fig. 1 Illustration of the multifunctional nanoplatform based on MSNs.






Fig. 2 TEM images of C-dots (a, d), MSN@C-dots nanoparticles (b, e) and MSN@C-dots/RB nanoparticles (c, f).

that the content of carbon element in MSN@C-dots nanoparticles was significantly higher than the MSNs, demonstrating success embedding of C-dots in the MSNs (Fig. S1†). According to thermogravimetric analysis (TGA), the content of C-dots in the MSN@C-dots nanoparticles was quantified to be 0.41% (w/w) (Fig. S2†). It should be noted that the uniform morphologies of MSN@C-dots can not be obtained at the higher doping concentration of C-dots (Fig. S3†). In order to achieve the PDT efficacy and more drug-loaded capacity, a mesoporous silica shell was grown on MSN@C-dots nanoparticles for the photosensitizer RB embedding and drug loading. Then, RB was embedded in mesoporous silica shell by epitaxial growth of the MS shell surrounding the MSN@C-dots and the MSN@C-dots/RB nanoparticles were achieved. As shown in Fig. 2c and f, the resulting MSN@C-dots/RB nanoparticles have the core-shell structures, and their average size is  $104.2 \pm 6.0$  nm. In comparison with MSN@C-dots nanoparticles, the hydrodynamic diameter of MSN@C-dots/RB nanoparticles increased from 78.8 nm to 105.7 nm (Fig. S4†), owing to the mesoporous silica shell was epitaxial grown on MSN@C-dots nanoparticles. Compared with MSN@C-dots nanoparticles, thermogravimetric analysis (TGA) of the MSN@C-dots/RB nanoparticles showed more weight loss and different decomposition temperature, because the RB embedded in MSN@C-dots/RB nanoparticles (Fig. S2†). The content of RB in the MSN@C-dots/RB nanoparticles was determined to be 0.54% (w/w). These results suggest the mesoporous silica shell successfully epitaxial growing on MSN@C-dots nanoparticles and RB successfully embedding in the mesoporous silica shell.

The mesoporous structure of MSN@C-dots/RB nanoparticles were further characterized by  $N_2$  sorption technique. Fig. 3 showed the  $N_2$  adsorption–desorption isotherms and the corresponding pore size distributions of MSN@C-dots nanoparticles and MSN@C-dots/RB nanoparticles. The MSNs exhibit type IV isotherm, suggesting that the MSNs have mesoporous structure.<sup>18</sup> After epitaxial growing of a mesoporous silica shell, the  $N_2$  adsorption amount of the nanoparticles achieved a significant increase. The pore volume increased from  $0.3329 \text{ cm}^3 \text{ g}^{-1}$  to  $0.4003 \text{ cm}^3 \text{ g}^{-1}$  and BET surface area increased from




Fig. 3  $N_2$  adsorption–desorption isotherms and pore size distribution curve (inset) of MSN@C-dots nanoparticles (a) and MSN@C-dots/RB nanoparticles (b).

$170.8866 \text{ m}^2 \text{ g}^{-1}$  to  $379.1326 \text{ m}^2 \text{ g}^{-1}$ , respectively. In the meantime, the mesopore average size increased from 2.0 to 3.0 nm. The increase in pore volume, surface area, and mesopore size indicated the potentially enhanced drug loading capacity of MSN@C-dots/RB nanoparticles compared with MSN@C-dots nanoparticles.

#### Optical properties and loading capacity of the MSN@C-dots/RB nanoparticles

The optical properties of the as-prepared nanoparticles had been further explored. As shown in Fig. 4a, MSN@C-dots nanoparticles showed distinct excitation-independent photoluminescence property, which was similar to the pure C-dots and indicated the C-dots were homogeneously embedded in the MSN@C-dots.<sup>23</sup> The fluorescence emission of C-dots may be surface-state emission, where the bandgap is affected by the particle size and surface properties of C-dots<sup>35,55</sup> After epitaxial growing a mesoporous silica shell on MSN@C-dots nanoparticles, MSN@C-dots/RB nanoparticles show a broad emission band ranged from 570 nm to 660 nm, and RB emission peak and intensity was nearly unchanged (Fig. 4b), which indicated the interaction between C-dots and RB was relatively weak.

In order to evaluate the RB loading capability and the stability of MSN@C-dots/RB nanoparticles, we performed a loading and release study of the RB in MSN@C-dots/RB








Fig. 4 (a) The emission spectra of MSN@C-dots nanoparticles under different excitation. (b) The emission spectra of RB (black line), MSN@C-dots nanoparticles (red line) and MSN@C-dots/RB nanoparticles (blue line). The insets (from left to right) show photographs of MSNs, MSN@C-dots nanoparticles and MSN@C-dots/RB nanoparticles dispersed in aqueous solution.

nanoparticles. From the PL spectrum of MSN@C-dots/RB nanoparticles soaked in phosphate-buffered saline (PBS,  $0.25 \text{ mg mL}^{-1}$ ) (Fig. S5†), the content of RB in the MSN@C-dots/RB nanoparticles was quantified to be 0.52% (w/w), which is consistent with the TGA result. Moreover, it was found that a negligibly low content of RB was released from MSN@C-dots/RB nanoparticles even for 72 h soaked in PBS buffer with varying pH (5.0, 6.0, 6.5, 7.0) (Fig. S6†), which verifies the high stability of the MSN@C-dots/RB nanoparticles. The cytotoxicity of MSN@C-dots/RB nanoparticles was measured on human embryo lung fibroblast cell line (HELFL) by using a MTT assay. The cell viability was determined to be higher than 90% even at a high concentration of  $100 \mu\text{g mL}^{-1}$  for MSN@C-dots/RB nanoparticles (Fig. S7†). The high cell viability infers that MSN@C-dots/RB is biocompatible and nearly nontoxic to cells.

Then, the drug loading and delivery capability of MSN@C-dots/RB nanoparticles was demonstrated by the pH-dependent DOX release. From the UV-Vis spectra of the DOX solution (Fig. S8†), the content of DOX loading in the MSN@C-dots/RB nanoparticles was quantified to be 34.4% (w/w) and the loading efficiency of DOX was 82.6%. Notably, MSN@C-dots/RB nanoparticles have ultralow drug cumulative release amount at neutral condition, exhibiting a low value of about 17.9% over the course of 24 h. A substantial increase of drug release rate was observed in acidic solutions, the cumulative release of

MSN@C-dot/RB nanoparticles reached about 50.5% at pH 5.0 over the course of 24 h (Fig. S9†). Due to acidic extracellular microenvironment around tumour, the above pH-dependent release properties of MSN@C-dots/RB nanoparticles were favorable for increasing the cancer therapy efficacy and reducing the side effects.

#### *In vitro* anticancer effect and cell imaging of the MSN@C-dots/RB nanoparticles

To explore the PDT effect of MSN@C-dots/RB nanoparticles, the production of  $^1\text{O}_2$  in MSN@C-dots/RB nanoparticles was firstly detected by measuring the bleaching of 1,3-diphenylisobenzofuran (DPBF), whose absorbance at 415 nm would be diminished in the presence of  $^1\text{O}_2$ . As shown in Fig. 5a, the absorbance of DPBF remained nearly unchanged in the control experiments (MSN@C-dots nanoparticles with light irradiation or MSN@C-dots/RB nanoparticles without light irradiation), indicating the absence of  $^1\text{O}_2$  production. By contrast, the absorbance of DPBF incubated with MSN@C-dots/RB nanoparticles decreased exponentially with the time under 540 nm light irradiation at a power of  $300 \text{ mW cm}^{-2}$  and decreased approximately 70% in 10 min, indicating a high  $^1\text{O}_2$  production.




Fig. 5 (a) Time-dependent bleaching of DPBF caused by  $^1\text{O}_2$  generation in the presence of MSN@C-dots/RB nanoparticles under 540 nm light irradiation. All the absorbances were normalized at the zero point of irradiation time. (b) The cell viability of H1299 cells treated with different concentrations of MSN@C-dots/RB nanoparticles and MSN@C-dots/RB/DOX nanoparticles with or without green light irradiation. (c) The corresponding microscopic images of H1299 cells treated with different concentrations of MSN@C-dots/RB nanoparticles under green light irradiation.



These results unambiguously demonstrated that the generation of  $^1\text{O}_2$  was triggered by MSN@C-dots/RB nanoparticles upon green light excitation. Notably, compared with the same amount of RB solution,  $^1\text{O}_2$  production of MSN@C-dots/RB nanoparticles was about 1.4 times higher under light irradiation (Fig. 5a). The excellent  $^1\text{O}_2$  production efficiency of the MSN@C-dots/RB nanoparticles is due to the mesoporous silica matrix can effectively inhibit the self-aggregation of RB and the core/shell structure decrease the interaction of excited RB and C-dots.

In this study, *in vitro* cytotoxicity of the MSN@C-dots/RB nanoparticles to cancer cells H1299 using a MTT assay was investigated to evaluate PDT efficiency of this MSNs based nanoplatform. As shown in Fig. 5b, upon 540 nm light irradiation at a relatively low power of  $300 \text{ mW cm}^{-2}$  for 5 min, a significant reduction in cell viability was observed for H1299 cells incubated with MSN@C-dots/RB nanoparticles, in stark contrast to those incubated with MSN@C-dots/RB nanoparticles without light irradiation. The corresponding microscopic images of H1299 cells clearly showed the remarkable changes of cell morphology and an increased cell death with the increasing concentration of MSN@C-dots/RB nanoparticles (Fig. 5c), which were consistent with the results of cell viability acquired from MTT assays.

To investigate the synergistic effects of PDT with chemotherapy, three control groups (MSN@C-dots/DOX, MSN@C-dots/RB/DOX without light irradiation, MSN@C-dots/RB with light irradiation) were carried out to treat with H1299 cells, followed by the MTT assay test. The mono-therapy groups, MSN@C-dots/DOX and MSN@C-dots/RB/DOX without light irradiation, exhibited moderate cytotoxicity to H1299 cells (Fig. S10<sup>†</sup> and 5b). In addition, the trend of the reduction that H1299 cells incubated with MSN@C-dots/RB/DOX nanoparticles without light irradiation was relatively faster than MSN@C-dots/DOX group, illustrating the high DOX loading capacity of MSN@C-dots/RB nanocomposites (Fig. S10<sup>†</sup>). Furthermore, by employing the combined therapy group (MSN@C-dot/RB/DOX with light irradiation), the greatest reduction in cell viability was observed. Specifically, only 6.8% cell viability of H1299 cells was tested at the concentration of  $30 \mu\text{g mL}^{-1}$  MSN@C-dot/RB/DOX nanoparticles (Fig. 5b). The combined therapy group exhibited a remarkably improved therapy relative to that of single chemotherapy or PDT group. These results confirm the high therapeutic efficacy of MSN@C-dot/RB/DOX nanoparticles *in vitro*, and thus show great promise of developing MSN@C-dot/RB/DOX nanoparticles as an efficient anticancer agent in biological or clinical applications.

Besides chemo/photodynamic therapy, the MSN@C-dots/RB nanoparticles could be also used for cancer cell imaging by utilizing their intense photoluminescence. After incubation with H1299 cells, the red emission of C-dots from the MSN@C-dots/RB nanoparticles was clearly visualized in the cytoplasm upon 540 nm light irradiation (Fig. 6 a). These results show that the MSNs-based nanoplatform may serve as a fluorescence imaging agent for imaging-guided synergistic chemotherapy and PDT therapy, where the photoluminescence of the C-dots can be used to monitor cancer cells, the photosensitizer can




Fig. 6 Confocal microscopy images of H1299 cells incubated with MSN@C-dots/RB nanoparticles for 2 h at  $37^\circ\text{C}$ . (a) The C-dots red emission image of MSN@C-dots/RB nanoparticles ( $\lambda_{\text{em}} = 590\text{--}680 \text{ nm}$ ,  $\lambda_{\text{ex}} = 552 \text{ nm}$ ), (b) the RB green emission image of MSN@C-dots/RB nanoparticles ( $\lambda_{\text{em}} = 565\text{--}590 \text{ nm}$ ,  $\lambda_{\text{ex}} = 552 \text{ nm}$ ) and (c) the Hoechst blue emission image MSN@C-dots/RB nanoparticles ( $\lambda_{\text{em}} = 450\text{--}490 \text{ nm}$ ,  $\lambda_{\text{ex}} = 405 \text{ nm}$ ). (d) The overlay image of (a)–(c).

be used to generate  $^1\text{O}_2$  for photodynamic therapy, and the mesoporous structure can be utilized to loading drugs for chemotherapy.

#### Antimicrobial activity of the MSN@C-dots/RB nanoparticles

Since frequently the bacterial infection contamination accompanying cancer progression can injure the immune system and deteriorate cancers, bacterial inhibition ability of MSN@C-dots/RB nanoparticles also had been investigated. To explore the bacterial inhibitory effect, we researched *E. coli* growth kinetics in liquid Luria–Bertani (LB) media by measuring the optical density (OD) at 600 nm of the bacterial suspensions. Fig. 7a illustrated the values of the  $\text{OD}_{600}$  that *E. coli* treated with different concentrations of MSN@C-dots/RB nanoparticles with green light irradiation at different incubation times. With increasing the concentrations of MSN@C-dots/RB nanoparticles, the growth of *E. coli* was progressively inhibited, which indicated MSN@C-dots/RB nanoparticles have a dose-dependent manner at bacterial inhibiting. When the concentration of MSN@C-dots/RB nanoparticles reached to  $100 \mu\text{g mL}^{-1}$ , the bacterial growth of *E. coli* was delayed about 12 h under green light irradiation. To further explore MSN@C-dots/RB nanoparticles as a nanocarrier's platform, the effect of MSN@C-dots/RB nanoparticles was investigated by loading an antibacterial agent of ampicillin (Amp) in MSN@C-dots/RB nanoparticles (loading capacity: 18.3% (w/w), loading efficiency: 29.3%, Fig. S11<sup>†</sup>). The antibacterial effect of such platform (MSN@C-dots/RB/Amp) without light irradiation were firstly investigated. As shown in Fig. S12,<sup>†</sup> the growth of *E. coli* was gradually suppressed with increasing MSN@C-dots/RB/Amp concentration, illustrating the antibacterial effect of






Fig. 7 (a) The growth curve of *E. coli* treated with different concentrations of MSN@C-dots/RB under green light irradiation. (b) The growth curve of *E. coli* treated with different concentrations of MSN@C-dots/RB-Amp under green light irradiation. (c) The photographs of *E. coli* colonies formed on LB-agar plates after treatments with MSN@C-dots/RB nanoparticles. From left to right: control, MSN@C-dots/RB without light irradiation, MSN@C-dots/RB with light irradiation and MSN@C-dots/RB/Amp with light irradiation.

Amp. In comparison, MSN@C-dots/RB/Amp with light irradiation group exhibited more remarkable inhibitory effect, and the growth of *E. coli* was significantly suppressed with otherwise identical conditions (Fig. 7b). When the concentration of MSN@C-dots/RB/Amp nanoparticles reached to  $100 \mu\text{g mL}^{-1}$ , the *E. coli* were almost completely killed. These results reveal great potential of the MSN@C-dot/RB/Amp nanoparticles as a dual-mole antibacterial agents for antimicrobial treatment.

The agar plate experiments of *E. coli* were also evaluated the antibacterial effect of MSN@C-dots/RB nanoparticles. The concentration of MSN@C-dots/RB nanoparticles was  $100 \mu\text{g mL}^{-1}$ . The photos of bacterial colonies clearly displayed on the corresponding agar plates and indicated the differences in bacterial inhibiting effects (Fig. 7c). Compared with the control plate, the *E. coli* incubated with MSN@C-dots/RB nanoparticles without light irradiation showed little difference in the number of *E. coli* colonies indicating MSN@C-dots/RB nanoparticles cannot inhibit bacteria by themselves. In contrast, the number of *E. coli* colonies showed significant reduction under green light irradiation, which confirmed the antibacterial effect of MSN@C-dots/RB nanoparticles was obtained by the generation of  $^1\text{O}_2$  under light irradiation (Fig. 7c). For the *E. coli* treated with MSN@C-dots/RB/Amp nanoparticles under the green light irradiation, there was no visible bacterial colonies lawn on the plate suggesting the complete inhibiting effect at  $100 \mu\text{g mL}^{-1}$ . These results demonstrated MSN@C-dots/RB nanoparticles could effectively inhibit the growth of *E. coli* under light irradiation and hold great potential in the bacteria inhibiting field.

## Conclusions

In summary, we have developed a general strategy to fabricate a multifunctional nanopatform MSN@C-dots/RB, in which carbon dots embedded in MSNs core, photosensitizers RB

doped in mesoporous silica shell and the drugs loaded in mesoporous silica channel. Core/shell structure of MSNs has been smartly designed to prevent the self-aggregation of carbon dots and photosensitizers, avoid the mutual interference between them, and increase the loading capacity of drugs. All of these advantages are critical for improving cancer therapy efficacy than that of single chemotherapy or PDT group. In particular, compared with the pure RB, 1.4 times higher  $^1\text{O}_2$  production has been achieved in our multifunctional nanopatform upon 10 min light irradiation. And the enhanced anticancer efficacy has been obtained by the combined chemo/photodynamic therapy. More than 90% reduction in cell viability has been achieved at the concentration of  $30 \mu\text{g mL}^{-1}$  MSN@C-dot/RB/DOX nanoparticles under light irradiation. Moreover, by taking advantages of the red PL of the carbon dots embedded in MSN@C-dots/RB, we have demonstrated their potential as a nanopatform for imaging-guided chemo/photodynamic therapy. Finally, we have shown the high efficacy of the MSN@C-dots/RB for the inhibition of bacteria. Therefore, the MSN@C-dots/RB nanoparticles are a promising multifunctional nanopatform for enhancing the therapeutic efficiency in medicine therapy.

## Acknowledgements

We greatly thank the financial supports from the National Nature Science Foundation of China (31270790, 31300650 and 31470741), the National Thousand Talents Program of China, and China Postdoctoral Science Foundation (2016M592096). We wish to thank Dr Lei Zhang for many helpful discussions.

## References

- 1 L. Cheng, C. Wang, L. Feng, K. Yang and Z. Liu, *Chem. Rev.*, 2014, **114**, 10869–10939.
- 2 T. Lammers, F. Kiessling, W. E. Hennink and G. Storm, *Mol. Pharm.*, 2010, **7**, 1899–1912.
- 3 J. Kim, Y. Piao and T. Hyeon, *Chem. Soc. Rev.*, 2009, **38**, 372–390.
- 4 J. P. Celli, B. Q. Spring, I. Rizvi, C. L. Evans, K. S. Samkoe, S. Verma, B. W. Pogue and T. Hasan, *Chem. Rev.*, 2010, **110**, 2795–2838.
- 5 H. Gong, Z. Dong, Y. Liu, S. Yin, L. Cheng, W. Xi, J. Xiang, K. Liu, Y. Li and Z. Liu, *Adv. Funct. Mater.*, 2014, **24**, 6492–6502.
- 6 Z. Zhang, L. Wang, J. Wang, X. Jiang, X. Li, Z. Hu, Y. Ji, X. Wu and C. Chen, *Adv. Mater.*, 2012, **24**, 1418–1423.
- 7 S. S. Lucky, N. Muhammad Idris, Z. Li, K. Huang, K. C. Soo and Y. Zhang, *ACS Nano*, 2015, **9**, 191–205.
- 8 K. Lu, C. He, N. Guo, C. Chan, K. Ni, R. R. Weichselbaum and W. Lin, *J. Am. Chem. Soc.*, 2016, **138**, 12502–12510.
- 9 Y. Wang, H. Wang, D. Liu, S. Song, X. Wang and H. Zhang, *Biomaterials*, 2013, **34**, 7715–7724.
- 10 B. Sun, B. Ranganathan and S.-S. Feng, *Biomaterials*, 2008, **29**, 475–486.
- 11 F. Tang, L. Li and D. Chen, *Adv. Mater.*, 2012, **24**, 1504–1534.





- 12 J.-N. Liu, W.-B. Bu and J.-L. Shi, *Acc. Chem. Res.*, 2015, **48**, 1797–1805.
- 13 N. Erathodiyil and J. Y. Ying, *Acc. Chem. Res.*, 2011, **44**, 925–935.
- 14 H. Meng, M. Xue, T. Xia, Z. Ji, D. Y. Tarn, J. I. Zink and A. E. Nel, *ACS Nano*, 2011, **5**, 4131–4144.
- 15 P. Yang, S. Gai and J. Lin, *Chem. Soc. Rev.*, 2012, **41**, 3679–3698.
- 16 E.-K. Lim, T. Kim, S. Paik, S. Haam, Y.-M. Huh and K. Lee, *Chem. Rev.*, 2015, **115**, 327–394.
- 17 L. Zhang, Y. Chen, Z. Li, L. Li, P. Saint-Cricq, C. Li, J. Lin, C. Wang, Z. Su and J. I. Zink, *Angew. Chem., Int. Ed.*, 2016, **128**, 2158–2161.
- 18 Y.-S. Lin, S.-H. Wu, Y. Hung, Y.-H. Chou, C. Chang, M.-L. Lin, C.-P. Tsai and C.-Y. Mou, *Chem. Mater.*, 2006, **18**, 5170–5172.
- 19 L. Li, F. Tang, H. Liu, T. Liu, N. Hao, D. Chen, X. Teng and J. He, *ACS Nano*, 2010, **4**, 6874–6882.
- 20 I. Slowing, B. G. Trewyn and V. S.-Y. Lin, *J. Am. Chem. Soc.*, 2006, **128**, 14792–14793.
- 21 E. Gandin, Y. Lion and A. Van de Vorst, *Photochem. Photobiol.*, 1983, **37**, 271–278.
- 22 E. Gianotti, B. Martins Estevão, F. Cucinotta, N. Hioka, M. Rizzi, F. Renò and L. Marchese, *Chem.–Eur. J.*, 2014, **20**, 10921–10925.
- 23 J. Gehring, B. Trepka, N. Klinkenberg, H. Bronner, D. Schleheck and S. Polarz, *J. Am. Chem. Soc.*, 2016, **138**, 3076–3084.
- 24 H. Liu, Y. Yang, A. Wang, M. Han, W. Cui and J. Li, *Adv. Funct. Mater.*, 2016, **26**, 2561–2570.
- 25 A. Yildirim, M. Turkyaydin, B. Garipcan and M. Bayindir, *RSC Adv.*, 2016, **6**, 32060–32069.
- 26 J. Zhan, Z. Ma, D. Wang, X. Li, X. Li, L. Le, A. Kang, P. Hu, L. She and F. Yang, *Int. J. Nanomed.*, 2017, **12**, 2733.
- 27 J. G. Croissant, X. Cattoën, J.-O. Durand, M. W. C. Man and N. M. Khashab, *Nanoscale*, 2016, **8**, 19945–19972.
- 28 G. Yang, H. Gong, X. Qian, P. Tan, Z. Li, T. Liu, J. Liu, Y. Li and Z. Liu, *Nano Res.*, 2015, **8**, 751–764.
- 29 M. Gary-Bobo, Y. Mir, C. Rouxel, D. Brevet, I. Basile, M. Maynadier, O. Vaillant, O. Mongin, M. Blanchard-Desce, A. Morère, M. Garcia, J. O. Durand and L. Raehm, *Angew. Chem., Int. Ed.*, 2011, **123**, 11627–11631.
- 30 D. Brevet, M. Gary-Bobo, L. Raehm, S. Richeter, O. Hocine, K. Amro, B. Loock, P. Couleaud, C. Frochot and A. Morère, *Chem. Commun.*, 2009, 1475–1477.
- 31 T. Wang, L. Zhang, Z. Su, C. Wang, Y. Liao and Q. Fu, *ACS Appl. Mater. Interfaces*, 2011, **3**, 2479–2486.
- 32 D. Shen, J. Yang, X. Li, L. Zhou, R. Zhang, W. Li, L. Chen, R. Wang, F. Zhang and D. Zhao, *Nano Lett.*, 2014, **14**, 923–932.
- 33 S. Y. Lim, W. Shen and Z. Gao, *Chem. Soc. Rev.*, 2015, **44**, 362–381.
- 34 P. Miao, K. Han, Y. Tang, B. Wang, T. Lin and W. Cheng, *Nanoscale*, 2015, **7**, 1586–1595.
- 35 S. Qu, D. Zhou, D. Li, W. Ji, P. Jing, D. Han, L. Liu, H. Zeng and D. Shen, *Adv. Mater.*, 2016, **28**, 3516–3521.
- 36 L. Cao, X. Wang, M. J. Mezziani, F. Lu, H. Wang, P. G. Luo, Y. Lin, B. A. Harruff, L. M. Veca, D. Murray, S.-Y. Xie and Y.-P. Sun, *J. Am. Chem. Soc.*, 2007, **129**, 11318–11319.
- 37 S. N. Baker and G. A. Baker, *Angew. Chem., Int. Ed.*, 2010, **49**, 6726–6744.
- 38 Y. Liu, Y. Tian, Y. Tian, Y. Wang and W. Yang, *Adv. Mater.*, 2015, **27**, 7156–7160.
- 39 X. Jia, M. Pei, X. Zhao, K. Tian, T. Zhou and P. Liu, *ACS Biomater. Sci. Eng.*, 2016, **2**, 1641–1648.
- 40 Q. Wang, S. Zhang, Y. Zhong, X.-F. Yang, Z. Li and H. Li, *Anal. Chem.*, 2017, **89**, 1734–1741.
- 41 Y. Wang and A. Hu, *J. Mater. Chem. C*, 2014, **2**, 6921–6939.
- 42 Y. Chen, M. Zheng, Y. Xiao, H. Dong, H. Zhang, J. Zhuang, H. Hu, B. Lei and Y. Liu, *Adv. Mater.*, 2016, **28**, 312–318.
- 43 D. Zhou, D. Li, P. Jing, Y. Zhai, D. Shen, S. Qu and A. L. Rogach, *Chem. Mater.*, 2017, **29**, 1779–1787.
- 44 T. H. Kim, F. Wang, P. McCormick, L. Wang, C. Brown and Q. Li, *J. Lumin.*, 2014, **154**, 1–7.
- 45 Z. Xie, F. Wang and C. y. Liu, *Adv. Mater.*, 2012, **24**, 1716–1721.
- 46 F. Wang, Z. Xie, H. Zhang, C. y. Liu and Y. g. Zhang, *Adv. Funct. Mater.*, 2011, **21**, 1027–1031.
- 47 Y. Chen, B. Lei, M. Zheng, H. Zhang, J. Zhuang and Y. Liu, *Nanoscale*, 2015, **7**, 20142–20148.
- 48 Y. Liu, C.-y. Liu, Z.-y. Zhang, W.-d. Yang and S.-d. Nie, *J. Mater. Chem. C*, 2015, **3**, 2881–2885.
- 49 X. Liu, N. Zhang, T. Bing and D. Shangguan, *Anal. Chem.*, 2014, **86**, 2289–2296.
- 50 C. Liu, L. Bao, B. Tang, J. Y. Zhao, Z. L. Zhang, L. H. Xiong, J. Hu, L. L. Wu and D. W. Pang, *Small*, 2016, **12**, 4702–4706.
- 51 C. Cheng, X. Tan, D. Lu, L. Wang, T. Sen, J. Lei, A. M. El-Toni, J. Zhang, F. Zhang and D. Zhao, *Chem.–Eur. J.*, 2015, **21**, 17944–17950.
- 52 R. Liu, D. Wu, S. Liu, K. Koynov, W. Knoll and Q. Li, *Angew. Chem., Int. Ed.*, 2009, **121**, 4668–4671.
- 53 L. Zhou, Z. Li, Z. Liu, J. Ren and X. Qu, *Langmuir*, 2013, **29**, 6396–6403.
- 54 G. Bucaneve, A. Micozzi, F. Menichetti, P. Martino, M. S. Dionisi, G. Martinelli, B. Allione, D. D'antonio, M. Buelli and A. M. Nosari, *N. Engl. J. Med.*, 2005, **353**, 977–987.
- 55 L. Bao, C. Liu, Z.-L. Zhang and D.-W. Pang, *Adv. Mater.*, 2015, **27**, 1663–1667.

